CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Carcinoembryonic Antigen (CEA) Testing

Policy governing coverage and medical necessity of serum CEA testing for monitoring certain malignancies for Blue Cross Blue Shield - Rhode Island members, affecting ordering providers and laboratories.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyCarcinoembryonic Antigen (CEA) Testing

Policy CodePolicy N/A

Change TypeAdministrative revision — no material clinical changes

Effective DateMay 1, 2026

Next Review DateJun 5, 2026

Key ActionWhen filing CPT 82378, ensure it is submitted with a covered diagnosis from the BCBSRI ICD-10 list to be considered medically necessary.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

82378Medically necessary code

every 2-3 moASCO postop frequency

Medicare & CommercialCoverage varies by product

Not applicablePrior auth

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Primary coverage conditions: 1) The test performed is CPT code 82378 (Carcinoembryonic antigen, CEA); 2) The service is filed with one of the covered diagnosis codes listed in the BCBSRI ICD-10 Diagnosis List for 82378; 3) The indication is for monitoring or management of malignancy that expresses CEA (examples: follow-up of colorectal carcinoma, monitoring response in metastatic solid tumors that express CEA, preoperative or postoperative assessment to evaluate adequacy of resection and to guide management).

ASCO guidance: post-operative CEA testing every 2–3 months for at least two years is recommended for patients with initial stage II or III colorectal cancer when resection of liver metastasis would be considered.

All other indications for Carcinoembryonic Antigen (CEA) testing are not covered for Medicare Advantage and not medically necessary for Commercial Products when there is no evidence that the technology improves net health outcome. CEA testing is only covered when filed with a covered diagnosis as specified in the Coding section.

CEA testing performed for indications other than a covered diagnosis is not medically necessary for Commercial Products and is not covered for Medicare Advantage when the test is not filed with one of the covered diagnosis codes. Coverage is dependent on the presence of an appropriate ICD-10 diagnosis code as listed in the BCBSRI coding requirements.

Covered Indications

inv-12: Monitoring response to therapy and follow-up of colorectal carcinoma and metastatic solid tumors expressing CEA; preoperative and postoperative assessment to evaluate adequacy of resection and guide management.

Covered when ALL of the following are met:

CEA monitoring and follow-up indications: 1) Monitoring response to therapy in patients with metastatic solid tumors that express CEA (measure at start of treatment and with subsequent treatment cycles to assess response); 2) Follow-up surveillance of colorectal carcinoma, including postoperative monitoring to evaluate adequacy of resection and guide management; 3) Preoperative measurement when used to help determine postoperative adequacy of surgical resection.

For postoperative surveillance in patients with initial stage II or III colorectal cancer, ASCO recommends CEA testing every 2–3 months for at least two years after diagnosis.

Coding

Medically necessary CPT Code when filed with covered diagnosisCPTCovered

82378

Carcinoembryonic antigen (CEA)

Diagnosis requirement

Filing requirementCPT 82378 must be filed with one of the diagnosis codes listed in the BCBSRI ICD-10 Diagnosis List for 82378

Lookup resourceSee attachment: ICD-10 Diagnosis List for 82378 (BCBSRI)

Coverage dependencyMedical necessity determined only when CPT 82378 is submitted with a covered diagnosis from the list

Provider Actions & Billing Requirements

Prior Authorization

Prior authorization and coding requirement

Prior authorization: Not applicable. When filing CPT 82378 (Carcinoembryonic Antigen), it must be billed only with a covered diagnosis from the ICD-10 list in the Coding section.

Affected code: CPT 82378

Note

Ordering physician responsibility

Only the ordering physician may initiate or manage prior authorization, appeals, or other administrative processes related to prior authorization.

Note

Authorization process ownership

Only the ordering physician shall be involved in the authorization, appeal, or other administrative processes related to prior authorization.

Denial Risk

Laboratory-initiated authorization prohibited

Laboratories or third parties may not obtain authorizations or participate in the authorization process on behalf of the ordering physician. Services provided by a laboratory that were not authorized (when authorization is required by the ordering process) will be denied and billed as the financial liability of the participating laboratory; such actions may lead to severe provider network sanctions.

Ordering Requirements

Note

ORDERING REQUIREMENTS — ordering physician must own authorization process

Only the ordering physician may participate in authorization, appeals, or other administrative prior authorization processes; laboratories are prohibited from obtaining authorization on behalf of the ordering physician and may face sanctions for violations.

Do not use laboratory representatives or third parties to obtain authorization or prepare documentation for appeals.
If a laboratory supports any portion of the authorization process it will be deemed a policy violation and may result in termination from the BCBSRI provider network.

Background

BACKGROUND: Carcinoembryonic Antigen (CEA) is a tumor-associated protein used as a biochemical marker to monitor response to therapy in certain carcinomas, particularly colorectal cancer. CEA testing may be used for follow-up at treatment decision points, to assess adequacy of resection pre- and post-operatively, and to monitor metastatic tumors that express CEA. Per policy, CEA testing is covered only when filed with a covered diagnosis and is otherwise not covered or not medically necessary depending on product.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyCarcinoembryonic Antigen (CEA) Testing

Policy CodePolicy N/A

Change TypeAdministrative revision — no material clinical changes

Effective DateMay 1, 2026

Next Review DateJun 5, 2026

Key ActionWhen filing CPT 82378, ensure it is submitted with a covered diagnosis from the BCBSRI ICD-10 list to be considered medically necessary.

SourceLink

On This Page

OpenPayer

Carcinoembryonic Antigen (CEA) Testing

Coverage Criteria

Covered Indications

Frequency Limits

Coding

Provider Actions & Billing Requirements

Ordering Requirements

Not Covered

Background

Definitions